Correction to: Einarson TR, Pudas H, Zilbershtein R, Jensen R, Colin Vicente C, Piwko C, Hemels MEH. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. J Med Econ 2013 Sep;16(9):1096–1105. Epub 2013 Jul 31.
The authors have been made aware of minor errors in the Transparency section. HP is a Janssen employee not a consultant; MEHH is also a Janssen employee who is not mentioned in this section. Likewise, CP is a consultant to Janssen, who was also not mentioned. The section should read:
Transparency
Declaration of funding
This article was supported by Janssen Pharmaceutica NV, Beerse, Belgium.
Declaration of financial/other relationships
RJ, HP, and MEHH are employees of Janssen. TE, RZ, CV, and CP have received consultant/advisory board fees from Janssen. TE has received funding from the sponsor for this research. He has also received travel funding to present a portion of these results at the Latin American ISPOR conference in Mexico City, 2011. In the past, TE has received funding for unrelated work from Novo Nordisk, Lundbeck, BMS, Generex, and Janssen-Ortho.
Acknowledgements
The authors thank the following persons for medical advice and clinical input into this project: Jari Tiihonen, MD, PhD, Hospital of Niuvaniem; Antti Liuska, MD, Hospital district of Pohjois-Karjala; Ilkka Larmo, MD, HUS; Sirpa, MD, Lindroos, Health care district of Forssa.
These errors did not affect any of the study results or conclusions.